# US 10,766,954 B2 · Therapeutic antibodies for treatment of neurodegeneration

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,766,954 B2
- Document ID: US10766954B2
- Status: Granted
- Kind: B2
- Application number: 16/092,055
- Filed: 2017-04-05
- Published: 2019-10-31
- Granted: 2020-09-08
- Earliest claimed: 2016-04-06
- Assignees: Imago Pharmaceuticals, Inc.
- Applicants: Imago Pharmaceuticals, Inc.
- Inventors: Irene Griswold-Prenner; Karen Chen
- Web page: https://patentgrep.com/patent/US10766954B2

## CPC

- C07K 16/18: against material from animals or humans
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides therapeutic antibodies and methods for treatment of diseases associated with diseases associated with aggregation of α-synuclein, e.g., in the brain of a subject. Such methods provide administration of therapeutic antibodies to elicit a beneficial immunogenic response against aggregation of α-synuclein. The methods are particularly useful for prophylactic and therapeutic treatment of diseases associated with the formation of Lewy bodies, e.g., Parkinson's disease.

## Claims

### Claim 1

A therapeutic monoclonal antibody comprising the VL CDRs of SEQ ID NO:1, SEQ NO:2 and SEQ NO: 3 and comprising the VH CDRs of SEQ ID NO:4, SEQ NO:5 and SEQ NO: 6.

### Claim 2 (depends on 1)

The therapeutic antibody of claim 1, wherein the antibody comprises a VH region having substantial identity to SEQ NO:8.

### Claim 3 (depends on 1)

The therapeutic antibody of claim 1, wherein the antibody is a humanized monoclonal antibody.

### Claim 4 (depends on 3)

The therapeutic antibody of claim 3, wherein the humanized antibody comprises a heavy chain region of the isotype IgG1, IgG2, IgG3, or IgG4.

### Claim 5 (depends on 3)

The therapeutic antibody of claim 3, wherein the humanized antibody is an Fv, scFv, Fab, F(ab′)2, or Fab′.

### Claim 6 (depends on 1)

A method of treating a disease characterized by a-synuclein aggregation comprising administering to a subject having or at risk of the disease a therapeutic antibody comprising an antibody of claim 1.

### Claim 7 (depends on 1, 6)

The method of claim 6, wherein the method comprises administering to a subject having or at risk of the disease a therapeutic antibody comprising an antibody of claim 1.

### Claim 8 (depends on 6)

The method of claim 6, wherein the disease is Parkinson's disease, Parkinson's disease with Alzheimer's disease, multiple system atrophy, or dementia with Lewy bodies.

### Claim 9 (depends on 6)

The method of claim 6, wherein the antibody is administered at a dosage of 0.0001 to 100 mg antibody/kg body weight.

### Claim 10 (depends on 6)

The method of claim 6, wherein the therapeutic antibody is administered with a pharmaceutical carrier.

### Claim 11 (depends on 6)

The method of claim 6, wherein the therapeutic antibody is administered in multiple dosages over at least six months.

### Claim 12 (depends on 6)

The method of claim 6, wherein the disease is Parkinson's disease.